1. Introduction {#s1}
===============

Major depressive disorder (MDD) is a common psychiatric illness that is often associated with cognitive dysfunction.^\[[@B1]\]^ One hypothesis about the mechanism of cognitive decline in MDD links it to decreasing acetylcholinesterase (AChE) activity of the cholinergic system in the hippocampus, frontal cortex, and septum.^\[[@B2]\]^ Some studies suggest that AChE inhibitors (e.g., donepezil,^\[[@B3]\]^ rivastigmine,^\[[@B4]\]^ and galantamine^\[[@B5]\]^) can ameliorate cognitive impairment in animal models of depression and in humans with MDD.^\[[@B5],\ [@B6],\ [@B7]\]^ Huperzine A (HupA) is a Traditional Chinese Medicine (TCM) isolated from Huperzineserrata (a genus of clubmosses), also known as ground pines or creeping cedar, in the family Lycopeodiaceae (a family of fern-allies). It is a powerful, highly specific, and reversible inhibitor of AChE.^\[[@B8],\ [@B9],\ [@B10]\]^ Because of its popularity as a TCM medication in mainland China, extensive clinical experience and research about HupA in China may help clarify the mechanism of action for its potential efficacy in the treatment of MDD. However, to date no systematic review or meta-analysis on HupA augmentation for MDD has been published. The primary aim of this study was to conduct a systematic review and meta-analysis about the efficacy and safety of HupA in the treatment of MDD based on published RCTs identified by searching international and Chinese databases.

2. Methods {#s2}
==========

2.1. Types of studies {#s2a}
---------------------

All publications of randomized controlled trials (RCTs) which reported on the efficacy and/or safety of antidepressants combined with HupA in the treatment of MDD were eligible for inclusion. Case reports/series, observational trials, meta-analyses, and systematic reviews were excluded.

2.2. Outcome measures {#s2b}
---------------------

The primary outcome measure of interest was cognitive function measured by the Wisconsin Card Sorting Test (WCST)^\[[@B11]\]^ or the Wechsler Memory Scale-Revised, Chinese version (WMS-RC).^\[[@B12]\]^ Key secondary outcomes were improvement in depressive and anxiety symptoms assessed by the Hamilton Depression Rating Scale (HAMD)^\[[@B13]\]^ and the Hamilton Anxiety Rating Scale (HAMA),^\[[@B14]\]^ self-reported quality of life assessed by the General Quality of Life Inventory of the World Health Organization (WHOQOL-100),^\[[@B15]\]^ causes for discontinuation of treatment, and adverse drug reactions measured by the Dosage Record Treatment Emergent Symptom Scale (DOTES).^\[[@B16]\]^ Clinical outcomes were based on intent-to-treat (ITT) analysis.

2.3. Selection of studies {#s2c}
-------------------------

PubMed, PsycINFO, Embase, Cochrane Library databases, the Cochrane Controlled Trials Register, ClinicalTrials.gov (<https://www.clinicaltrials.gov/>), and Chinese databases (WanFang Database, Chinese Biomedical database, and China Journal Net) were searched from the inception of the databases through March 12, 2016 using the following search terms: (Depressive Disorders OR Disorder, Depressive OR Disorders, Depressive OR Neurosis, Depressive OR Depressive Neuroses OR Depressive Neurosis OR Neuroses, Depressive OR Depression, Endogenous OR Depressions, Endogenous OR Endogenous Depression OR Endogenous Depressions OR Depressive Syndrome OR Depressive Syndromes OR Syndrome, Depressive OR Syndromes, Depressive OR Depression, Neurotic OR Depressions, Neurotic OR Neurotic Depression OR Neurotic Depressions OR Melancholia OR Melancholias OR Unipolar Depression OR Depression, Unipolar OR Depressions, Unipolar OR Unipolar Depressions) AND (Huperzine A OR Huperzine OR HupA) AND (randomized controlled trial OR controlled clinical trial OR randomized OR placebo OR drug therapy OR randomly OR trial OR groups). We also hand-searched reference lists from identified and relevant review articles for additional studies and contacted authors for unpublished data.

2.4. Data extraction {#s2e}
--------------------

Two authors (ZW and XYQ) independently conducted the literature search and extracted the data. Any disagreement was resolved by a third author (XYT). Data presented only in graphs and figures were extracted whenever possible. Authors were contacted to obtain missing information or clarification if possible. If cases were from multicenter studies, whenever possible, data were extracted separately for each center.

2.5. Statistical methods {#s2f}
------------------------

We used RevMan (version 5.1.7.0) in this meta-analysis according to the recommendations of the Cochrane Collaboration. For continuous data, weighted mean difference (WMD) with 95% CI was used to compare groups, and for dichotomous data, risk ratio (RR) with 95% confidence intervals (Cis) were computed to compare groups. The *I*^2^ statistic assessed statistical heterogeneity between the three studies: when *I*^2^≥50%, a random effects model was used;^\[[@B17]\]^ otherwise, a fixed effect model was employed.^\[[@B18]\]^ All analyses were two-tailed with alpha set at 0.05.

2.6. Risk of bias assessment {#s2g}
----------------------------

The methods of random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other biases were assessed using the Risk of Bias (ROB) scale developed to assess RCTs by the Cochrane Collaboration.^\[[@B19]\]^

3. Results {#s3}
==========

3.1. Results of the literature search {#s3a}
-------------------------------------

The search yielded 54 potentially relevant articles, of which four articles were published in English and 50 in Chinese. Of the 54 studies, 3 RCTs met the inclusion criteria.^\[[@B20],\ [@B21],\ [@B22]\]^ As shown in [Figure 1](#fig1){ref-type="fig"}, the total number of subjects included in the three studies was 238, with 119 receiving an antidepressant augmentated with HupA and 119 only receiving an antidepressant.

![Identification of included studies](sap-28-02-064-g002){#fig1}

3.2. The characteristics of included studies {#s3b}
--------------------------------------------

As shown in [Table 1](#table1){ref-type="table"}, all three RCTs ^\[[@B20],\ [@B21],\ [@B22]\]^ were conducted in China and used the criteria of the Chinese Classification of Mental Disorders, 3rd edition (CCMD-3)^\[[@B23]\]^ to diagnose depression. Males accounted for 45.4% of the sample (range 30% to 58% in the three studies), the weighted mean age of participants was 29.6 (range 16-60) years; and the weighted mean duration of illness was 3.3 (range 1.2 to 5.2) years. The weighted mean duration of the treatment trial reported in the studies was 6.7 (range 6-8) weeks. None of the studies were supported by pharmaceutical companies.

###### Characteristics of included studies

  ----------------------- ----- --------------------------------------- ------------------------ --------- ----------------------- ------------------------------------ ------------ ---------------------------------------------------------- ------------------------
  Study                   N     Design Settings                         Trial duration (weeks)   Country   Diagnosis\              Weighted mean age in years (range)   Male n (%)   Interventions:\                                            Outcome assessments
                                                                                                           Diagnostic criteria\                                                      \[M\] mean dose (mg/day)\                                  
                                                                                                           Mean illness duration                                                     \[R\] range (mg/day)\                                      
                                                                                                                                                                                     \[n\] number of patients                                   

  Gao 2007^\[[@B20]\]^    100   Open-label inpatients and outpatients   6                        China     MDD CCMD-3 5.2 years    30.4 (18-50)                         30 (30%)     1\. FLU(M=NR; R=20-40) + HupA (fixed dose at 0.3); n=50\   HAMD; WCST; WHOQOL-100
                                                                                                                                                                                     2. FLU(M=NR; R=20-40); n=50                                

  Yang 2010^\[[@B21]\]^   78    Open-label Inpatients and outpatients   8                        China     MDD CCMD-3 2.5 years    29.9 (18-60)                         45 (58%)     1\. FLU(M=NR; R=20-40) + HupA (fixed dose at 0.3); n=39\   HAMD; WMS-RC
                                                                                                                                                                                     2. FLU(M=NR; R=20-40); n=39                                

  Liu 2010^\[[@B22]\]^    60    Open-label Inpatients and outpatients   6                        China     MDD CCMD-3 1.2 years    27.9 (16-48)                         33 (55%)     1\. VEN(M=107; R=50-150) + HupA (M=NR; R=0.1-0.2); n=30\   HAMD; HAMA; DOTES
                                                                                                                                                                                     2. VEN(M=105; R=50-150); n=30                              
  ----------------------- ----- --------------------------------------- ------------------------ --------- ----------------------- ------------------------------------ ------------ ---------------------------------------------------------- ------------------------

^a^MDD, Major Depressive Disorder

CCMD-3, Chinese Mental Disorders Classification and Diagnostic Criteria, Third Edition^\[[@B23]\]^

FLU, fluoxetine

NR, not recorded

HupA, huperzine A

HAMD, Hamilton Depression Rating Scale^\[[@B13]\]^

WCST, Wisconsin Card Sorting Test^\[[@B11]\]^

WHOQOL-100, General Quality of Life Inventory of World Health Organization^\[[@B15]\]^

WMS-RC, Wechsler Memory Scale-Revised, Chinese version^\[[@B12]\]^

VEN, venlafaxine

HAMA, Hamilton Anxiety Rating Scale^\[[@B14]\]^

DOTES, Dosage Record Treatment Emergent Symptom Scale^\[[@B16]\]^

3.3. Assessment of risk of bias {#s3c}
-------------------------------

The risk of different types of biases of the three studies is shown in [Table 2](#table2){ref-type="table"}. Two studies^\[[@B21],\ [@B22]\]^ mentioned \"random\" assignment without a description of the method of randomizing, and one RCT^\[[@B20]\]^ was rated as high risk of selection bias because patients were classified into two groups according to the order of admission. None of the studies were blinded so the risk of allocation bias, performance bias, and detection bias were high. The studies reported the outcomes of all enrolled subjects, so the risk of attrition bias was low; but in the absence of study registration materials it was impossible to determine whether or not there was selective reporting (i.e., reporting bias). There was no evidence of other types of biases (e.g., drug company sponsorship of the study). Overall, all three studies were considered at high risk of bias and, thus, relatively low-quality studies.

###### 

Evaluation of risk of bias in the three included studies

  ----------------------- --------------------- --------------------------------- ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -------------------------------------
  study                   sequence generation   allocation sequence concealment   blinding of participants and personnel   blinding of outcome assessment   incomplete outcome data   selective outcome reporting   other potential threats to validity
  Gao 2007^\[[@B20]\]^    high                  high                              high                                     high                             low                       N/A                           low
  Yang 2010^\[[@B21]\]^   N/A                   high                              high                                     high                             low                       N/A                           low
  Liu 2010^\[[@B22]\]^    N/A                   high                              high                                     high                             low                       N/A                           low
  ----------------------- --------------------- --------------------------------- ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -------------------------------------

N/A=no information available

Because there were only three RCTs included in the meta-analysis, publication bias could not be tested.^\[[@B24]\]^

3.4. Changes in severity of depressive symptoms {#s3d}
-----------------------------------------------

In all three studies there were differences between groups in changes of the total HAMD score over the study period. As shown in [Figure 2](#fig2){ref-type="fig"}, one of the studies^\[[@B22]\]^ reported a significantly greater reduction of depressive symptoms (based on the HAMD) when adjunctive HupA was provided to patients with MDD being treated with antidepressants, but the other two studies did not find a significant advantage of adjunctive treatment with HupA. When pooling the three studies in a random effects meta-analysis, there was no statistically significant difference in the improvement in depressive symptoms between MDD patients who only received antidepressants and those who received antidepressants and adjunctive HupA.

![Adjunctive Huperzine A for MDD: forest plot for improvement in depressive symptoms assessed by change in total score of the Hamilton Depression Scale](sap-28-02-064-g003){#fig2}

3.5. Cognitive results {#s3e}
----------------------

The other results from the three studies are shown in [Table 3](#table3){ref-type="table"}. Only two studies^\[[@B20],\ [@B21]\]^ assessed the cognitive effects of the treatment. Both studies reported a significant advantage of using adjunctive HupA. In one study,^\[[@B21]\]^ memory functioning at the end of the 8-week trial was better in patients taking antidepressants with adjunctive HupA than in those who were only taking antidepressants. In another study,^\[[@B20]\]^ several measures of executive functioning derived from the WCST were significantly better at the end of the 6-week trial in depressed patients taking antidepressants with adjunctive HupA. These cognitive outcome measures were quite different so it was not possible to pool the results of the two studies into a meta-analysis.

###### Comparison of cognitive function, anxiety, and quality of life in patients with depression at end of course of treatment with either antidepressants and adjunctive HupA (experimental group) or with antidepressants alone (control group)

  --------------------------------- ------------------ --------------- ------------- -------------------- -------------- -------------- --------------------
  measure                           study              control group                 experimental group   t-test (*p*)                  
  n                                 mean (sd)                          n             mean (sd)                                          
  Cognitive measures                                                                                                                    
  WMS-RC                            Yang^\[[@B21]\]^   39              92.1 (16.7)                        39             103.0 (15.0)   3.04 (**0.003**)
  WCST (non-perseverative errors)   Gao^\[[@B20]\]^    50              35.7 (5.4)                         50             27.5 (8.5)     5.71 (**\<0.001**)
  WCST (perseverative errors)       Gao^\[[@B20]\]^    50              37.7 (7.4)                         50             26.4 (9.7)     6.60 (**\<0.001**)
  WCST (correct responses)          Gao^\[[@B20]\]^    50              24.3 (6.2)                         50             31.9 (11.3)    4.17 (**\<0.001**)
  WCST (categories completed)       Gao^\[[@B20]\]^    50              3.96 (0.83)                        50             4.52 (1.07)    2.92 (**0.004**)
  Anxiety (HAMA total score)        Liu^\[[@B22]\]^    30              8.1 (7.3)                          30             8.3 (7.3)      0.11 (0.909)
  WHOQOL-100 total score            Gao^\[[@B20]\]^    50              12.9 (3.9)                         50             18.6 (12.5)    3.08 (**0.003**)
  --------------------------------- ------------------ --------------- ------------- -------------------- -------------- -------------- --------------------

WMS-RC, Wechsler Memory Scale-Revised, Chinese version^\[[@B12]\]^

WCST, Wisconsin Card Sorting Test^\[[@B11]\]^

HAMA, Hamilton Anxiety Rating Scale^\[[@B14]\]^

WHOQOL-100, General Quality of Life Inventory of World Health Organization^\[[@B15]\]^

3.6. Other results {#s3f}
------------------

The level of anxiety was only assessed in one of the studies.^\[[@B22]\]^ Based on the total score of the HAMA at the end of the 6-week trial, there was no significant difference in the severity of anxiety symptoms between the two groups ([Table 3](#table3){ref-type="table"}).

Only one study^\[[@B20]\]^ assessed quality of life. As measured by WHOQOL-100,^\[[@B15]\]^ quality of life was significantly better at the end of the trial in individuals who received combined treatment with antidepressants and HupA ([Table 3](#table3){ref-type="table"}).

Only one study ^\[[@B22]\]^ assessed adverse reactions. The study assessed adverse events using the DOTES^\[[@B16]\]^ which considers tachycardia, dysuria, electrocardiographic abnormality, dry mouth, drowsiness, nausea, constipation, blurred vision, and insomnia. It found no difference in the prevalence of adverse events between the two treatment groups

None of the included RCTs reported the rate or causes of treatment discontinuation.

4. Discussion {#s4}
=============

4.1. Main finding {#s4a}
-----------------

Despite an extensive review of both English-language and Chinese-language literature, we only identified three RCTs that assessed the potential benefit of adjunctive HupA when treating individuals with depression who are currently using antidepressants. All three studies were open label and the outcome evaluation in the trials was not blinded, so the overall strength of the studies was rated as \'poor\'. The pooled sample from the three studies, all of which were published in Chinese, was 238 individuals, but it was only possible to conduct a meta-analysis for the results related to changes in depressive symptoms because other outcomes of interest (e.g., cognitive changes, quality of life changes, etc.) were only considered in one or two of the studies. Overall, the results suggest that adjunctive treatment with HupA over 6 to 8 weeks in patients with depression who are currently taking antidepressants does not result in a better reduction of depressive symptoms, but it does appear to lead to less cognitive impairment in depressed individuals and, possibly, to a better self-reported quality of life for depressed individuals.

4.2. Limitations {#s4b}
----------------

The small number of studies identified and the limited measures employed in the identified studies made it impossible to conduct a full meta-analysis, so we could not do a sensitivity analysis or subgroup analyses, and we could not construct a funnel plot to assess potential publication bias. Specifically, there were not enough studies with data on cognitive functioning to conduct a meta-analysis of this important outcome. Moreover, the relatively low quality of the available studies (open label, non-blinded) and the relatively short duration of the studies (from 6 to 8 weeks) means that the findings that were significant - the benefit of HupA augmentation for cognitive functioning and quality of life in depressed patients - are not robust; they need to be replicated in larger, methodologically more rigorous RCTs that follow participants for much longer.

4.3. Importance {#s4c}
---------------

Despite the limited number of RCTs identified and the methodological limitations of the identified studies,^\[[@B25]\]^ this review does provide some support for the suggestion that AChE inhibitors such as HupA can ameliorate the cognitive decline that is often associated with depression and, possibly, improve the quality of life of individuals being treated for depression with antidepressant medications. Similar to our findings, a recent meta-analyses^\[[@B26]\]^ found that adjunctive HupA is an effective choice for improving cognitive function in individuals with schizophrenia. The mechanism of action of HupA in improving cognitive functioning (or preventing cognitive decline) remains unknown, but given the importance of cognitive impairment in a wide range of mental disorders, further work in this promising area is merited.
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